Which olanzapine administration form requires monitoring for orthostatic hypotension, oversedation, delirium, and cardiorespiratory depression?

Which olanzapine administration form requires monitoring for orthostatic hypotension, oversedation, delirium, and cardiorespiratory depression?

• A. Olanzapine IM Short-Acting
• B. Olanzapine Nasal Spray
• C. Olanzapine IM Long-Acting
• D. Olanzapine Oral Tablet

Answer: (A)

The key idea is safety monitoring after administering a rapid-onset antipsychotic in acute agitation. The short-acting intramuscular form of olanzapine is given to quickly control agitation, but it can cause immediate CNS and autonomic effects: orthostatic hypotension from blood pressure drops, oversedation or excessive sleepiness, delirium or confusion, and potential cardiorespiratory depression, especially in patients who are already medically fragile or who are also receiving other sedatives. Because the effects can arise quickly after a shot, careful observation is needed for these signs as the medication takes effect and as the patient recovers. Other forms have different safety concerns: the long-acting injectable carries a risk of post-injection delirium/sedation syndrome requiring monitoring for several hours after administration, while the nasal spray and oral tablet generally present lower immediate risks for rapid, profound sedation or respiratory depression in the acute setting.

The key idea is safety monitoring after administering a rapid-onset antipsychotic in acute agitation. The short-acting intramuscular form of olanzapine is given to quickly control agitation, but it can cause immediate CNS and autonomic effects: orthostatic hypotension from blood pressure drops, oversedation or excessive sleepiness, delirium or confusion, and potential cardiorespiratory depression, especially in patients who are already medically fragile or who are also receiving other sedatives. Because the effects can arise quickly after a shot, careful observation is needed for these signs as the medication takes effect and as the patient recovers.

Other forms have different safety concerns: the long-acting injectable carries a risk of post-injection delirium/sedation syndrome requiring monitoring for several hours after administration, while the nasal spray and oral tablet generally present lower immediate risks for rapid, profound sedation or respiratory depression in the acute setting.